Patent Ductus Arteriosus After Premature Birth
12
2
3
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
33%
4 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (12)
Paracetamol Versus Ibuprofen in Premature Infants With Hemodynamically Significant Patent Ductus Arteriosus
Co-administration of Acetaminophen With Ibuprofen to Improve Duct-Related Outcomes in Extremely Premature Infants
Management of the PDA Trial
Prophylactic IV Paracetamol in Extremely Premature Infants
Selective Early Medical Treatment of Patent Ductus Arteriosus in Extremely Low Gestational Age Infants: A Pilot RCT
PDA Treatment With Ibuprofen and Changes in Tissue Oxygenation.
Oral Ibuprofen Versus Placebo in Treatment of Patent Ductus Arteriosus (PDA)in Preterm Infants
Hemodynamically Important Patent Ductus Arteriosus in Newborns Under 32 Weeks
Indomethacin PK-PD in Extremely Preterm Neonates
Combined Lung Ultrasounds and Transthoracic Electrical Bioimpedance in Preterm Infants With Respiratory Distress.
Timing of Surgical PDA Ligation and Neonatal Outcomes
The Effects of Phototherapy in Preterm Infants Pda